Get the Stockscreener App
1.10
4.76%
0.05
After Hours:
1.09
-0.01
-0.91%
Carisma Therapeutics Inc stock is traded at $1.10, with a volume of 214.60K.
It is up +4.76% in the last 24 hours and up +16.40% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$1.05
Open:
$1.07
24h Volume:
214.60K
Relative Volume:
1.53
Market Cap:
$45.43M
Revenue:
$14.92M
Net Income/Loss:
$-86.88M
P/E Ratio:
-0.3583
EPS:
-3.0699
Net Cash Flow:
$-82.31M
1W Performance:
+8.91%
1M Performance:
+16.40%
6M Performance:
-32.10%
1Y Performance:
-66.05%
1-Day Range:
$1.05
$1.10
1-Week Range:
$0.96
$1.10
52-Week Range:
$0.80
$3.4179
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
Carisma Therapeutics Inc Stock (CARM) Latest News
Carisma to present new data on CAR-M therapy for hepatocellular carcinoma - TipRanks
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - StreetInsider.com
Carisma Therapeutics, Inc. Announces to Present New Data on Anti-GPC3 in Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - Marketscreener.com
Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors - MyChesCo
Carisma Therapeutics (NASDAQ:CARM) Upgraded at EF Hutton Acquisition Co. I - Defense World
Carisma shares climb on EF Hutton Buy rating - Investing.com India
Carisma Therapeutics Appoints Sohanya Cheng to Board of Directors - citybiz
Carisma Therapeutics names Sohanya Cheng to board - Investing.com India
Carisma Therapeutics Announces Changes to its Board of Directors - Quantisnow
Carisma Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Carisma Therapeutics faces Nasdaq delisting over market value By Investing.com - Investing.com Australia
Carisma Therapeutics faces Nasdaq delisting over market value - Investing.com
Carisma Therapeutics to Showcase Cutting-Edge Cancer Research at SITC 2024 - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - Yahoo Finance
Carly Rae Jepsen is engaged! Canadian singer shares happy news on social media: 'Very engaged over here' - Yahoo Canada Shine On
Carly Rae Jepsen Flaunts Blue Engagement Ring with Grammy Winning Fiancé - 2paragraphs Buzz
CRDF (Cardiff Oncology Inc) has impressive results - US Post News
Berkley W R Corp Sells 451,295 Shares of Cartica Acquisition Corp (NASDAQ:CITE) - MarketBeat
Carly Rae Jepsen is a fiancée! Singer announces engagement to Grammy-winning producer - USA TODAY
Carly Rae Jepsen Engaged to Producer Cole MGN: See Her RingE! Online - E! NEWS
'Very engaged over here': Singer Carly Rae Jepsen announces her engagement to music producer Cole M.G.N. - 9Honey Celebrity
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Surprise! Carly Rae Jepsen Is Engaged!!! - PerezHilton.com
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now - Benzinga
Carly Rae Jepsen announces engagement to boyfriend Cole MGN after two years of dating - Daily Mail
Carly Rae Jepsen Proclaims Herself ‘Very Engaged Over Here’ in Photoshoot Showing Off Ring From Fiancé Cole M.G.N. - Billboard
Carly Rae Jepsen Engaged to Producer Cole M.G.N. - AceShowbiz Media
Carly Rae Jepsen & Boyfriend Cole M.G.N. Are Engaged! - Just Jared
Cole M.G.N. Entertainment News, Photos, and Videos - Just Jared
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
Hancock Whitney Corp Has $737,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Where Are They Now? Carisma Therapeutics - Life Science Leader Magazine
Gabelli Funds LLC Has $120.74 Million Stake in Crane (NYSE:CR) - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) PT Lowered to $40.00 at B. Riley - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
Selling Buzz: Accuray Inc [ARAY] SVP Chief Financial Officer Pervaiz Ali sells 8,404 shares of the company - Knox Daily
A company insider recently sold 833 shares of Apollo Commercial Real Estate Finance Inc [ARI]. Should You Sale? - Knox Daily
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 1-Year High at $21.10 - MarketBeat
An analyst sees good growth prospects for Capricor Therapeutics Inc (CAPR) - SETE News
CMR Bolsters Funding for Mineral Exploration - TipRanks
Quest Partners LLC Purchases Shares of 934 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Mutual of America Capital Management LLC Increases Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
CRISM Therapeutics Reports Positive Interim Results - TipRanks
Cairn Homes Advances Share Buyback Plan - TipRanks
Cero Therapeutics postpones special stockholders meeting By Investing.com - Investing.com Canada
Federated Hermes Inc. Sells 134 Shares of Cimpress plc (NASDAQ:CMPR) - Defense World
Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com
Federated Hermes Inc. Acquires 399,860 Shares of Costamare Inc. (NYSE:CMRE) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
Review: AfrAId (2024) - It's A Stampede!
BTIG Research gives a Neutral recommendation for Apollo Commercial Real Estate Finance Inc (ARI) - Knox Daily
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):